PUBLISHER: Grand View Research | PRODUCT CODE: 2132462
PUBLISHER: Grand View Research | PRODUCT CODE: 2132462
The global antibody drug conjugates contract development & manufacturing organization (CDMO) market size was valued at USD 9.4 billion in 2025 and is projected to grow from USD 10.5 billion in 2026 to USD 23.0 billion by 2033, at a CAGR of 11.9% from 2026 to 2033. The market in North America dominated with a revenue share of 43.8% in 2025. The market growth is driven by rapid expansion of the global ADC clinical pipeline, increasing approvals of ADC-based oncology therapies, and rising outsourcing of technically complex manufacturing activities.
In addition, the demand is supported by requirements for high-potency payload synthesis, linker development, site-specific conjugation, advanced analytical characterization, GMP bioconjugation, and sterile fill-finish. Besides, most biopharma companies are increasingly relying on specialized CDMOs to reduce capital investment, access containment infrastructure, and accelerate clinical-to-commercial scale-up.
In addition, growing adoption of integrated development models, commercial capacity expansions, and increasing investment in next-generation ADC platforms are strengthening long-term outsourcing demand across North America, Europe, and Asia Pacific.
Global Antibody Drug Conjugates CDMO Market Report Segmentation
This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the global antibody drug conjugates CDMO market report based on service, workflow, source, technology, therapeutic area, end use, and region.